A contract manufacturing organization (CMO) makes, packages or tests drug and device products for the company that owns them. This guide explains how a CMO differs from a CDMO and a CRO, why the owner's quality unit keeps release responsibility under 21 CFR 211.22(a) and 200.10(b) while a CRO can take over sponsor duties in writing under 21 CFR 312.52, what a quality agreement with a CMO has to assign, how often FDA cited owners for weak outsourcing controls on 774 drug and 377 device inspections from January 2025 to October 2026, and what recent Form 483s at contract facilities show.